Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Altogen Biosystems Launched GMP Grade Liver Targeted Transfection Reagent for In Vivo Delivery of Biomolecules

May 15, 2019

AUSTIN, Texas--(BUSINESS WIRE)--May 15, 2019--

First developed in 2012, Altogen’s liver-targetedin vivo transfection reagent has since been successfully used in over 25 research publications for liver tissue and tumor-specific delivery of therapeutic biomolecules such as siRNA, miRNA, mRNA, plasmid DNA, and small proteins. This efficient reagent was selected as the delivery vehicle of choice in several drug development programs; to better accommodate clinical programs, Altogen Biosystems announced the launch of real-time adaptive cGMP manufacturing of liver-targetedin vivo transfection reagent. This new product enables dose, formulation and product changes within a clinical protocol in response to emerging clinical data as well as targeted delivery to hepatocellular carcinoma cells and increased in vivo stability of cargo therapeutics. This novel liver-targeted delivery system may enable groundbreaking transfection efficiency medical applications including gene and oligonucleotides therapy of liver cancers.

Altogen Biosystems’ liver-targeted in vivo transfection reagent features liposome-based microscopic compounds coated with biodegradable polymers and attached to nucleic acids. Subsequent nanoparticle formation results from the binding of negatively charged nucleic acids to positively charged liposome-based particles. These biocompatible nanocomplexes act as nanocarriers into liver tissue and have displayed no adverse effects associated with the carrier application, a common obstacle for in vivo transfection. Biomolecule-loaded nanoparticles accumulate in target tissues post-administration and degrade over time. Altogen Labs performed GLP preclinical testing of the new liver-targeted in vivo reagent; results demonstrated enhanced stability in serum, tissue-targeted liver delivery of siRNA- and DNA-based therapeutic compounds, and no detectable inflammatory response.

About Altogen

Altogen Biosystems is a life sciences company that manufactures transfection products for in vitro and in vivo preclinical research and pharmaceutical applications. Altogen Biosystems provides over 120 transfection products for biomedical research, including cell type-specific transfection reagents, electroporation kits, and in vivo tissue-targeted delivery reagents.

Altogen Labs is a GLP-compliant laboratory providing both efficacy and toxicology testing for novel drugs. Company preclinical contract research services includes over 90 in-house validated xenograft models, pharm/tox assays (ADME, PK/PD, etc.), development of stable cell lines, and a myriad of RNAi and in vivo biodistribution/imaging studies.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190515006004/en/

CONTACT: Altogen Biosystems

Alex Fanelli, PhD

Phone: (702) 349-6103

Fax: (702) 989-0841




SOURCE: Altogen

Copyright Business Wire 2019.

PUB: 05/15/2019 05:05 PM/DISC: 05/15/2019 05:05 PM


All contents © copyright 2019 The Associated Press. All rights reserved.